losartan has been researched along with Anxiety in 9 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The angiotensin II receptor antagonist, DUP 753 (Losartan), was compared with diazepam for antianxiety properties in the rat using the elevated plus-maze." | 7.68 | Antianxiety properties of the angiotensin II antagonist, DUP 753, in the rat using the elevated plus-maze. ( Carr, RD; Fraser-Rae, L; Hallam, C; Kaiser, FC; Palmer, GC; Wallace, AV, 1992) |
| "Losartan was unable to improve hippocampal BDNF and IL-10 levels as well as the retention trial in the MWM task and depressive-like behaviors." | 5.56 | Losartan modulates brain inflammation and improves mood disorders and memory impairment induced by innate immune activation: The role of PPAR-γ activation. ( Baghcheghi, Y; Hosseini, M; Mokhtari-Zaer, A; Moradi-Marjaneh, R; Salmani, H, 2020) |
| "The antihypertensive drug losartan has been shown to improve memory in humans as well as learning and fear extinction in rodent models, highlighting its potential to have similar synergistic effects on exposure-based cognitive behavioral therapy for anxiety disorders." | 5.27 | Angiotensin Regulation of Amygdala Response to Threat in High-Trait-Anxiety Individuals. ( Browning, M; Craske, MG; Harmer, CJ; Kappelmann, N; Klein Breteler, J; Reinecke, A; Ressler, KJ, 2018) |
| "5μg) did not change the anxiety-like behavior of OBX rats, while losartan (100μg) showed an anxiolytic-like behavior, by increasing the number and time of open arms entries, the ratio of open/total entries and open/total time and decreasing the number and time of closed arm entries." | 3.88 | Involvement of hippocampal angiotensin 1 receptors in anxiety-like behaviour of olfactory bulbectomized rats. ( Ivanova, M; Tashev, R, 2018) |
| "The angiotensin II receptor antagonist, DUP 753 (Losartan), was compared with diazepam for antianxiety properties in the rat using the elevated plus-maze." | 3.68 | Antianxiety properties of the angiotensin II antagonist, DUP 753, in the rat using the elevated plus-maze. ( Carr, RD; Fraser-Rae, L; Hallam, C; Kaiser, FC; Palmer, GC; Wallace, AV, 1992) |
| "Losartan was unable to improve hippocampal BDNF and IL-10 levels as well as the retention trial in the MWM task and depressive-like behaviors." | 1.56 | Losartan modulates brain inflammation and improves mood disorders and memory impairment induced by innate immune activation: The role of PPAR-γ activation. ( Baghcheghi, Y; Hosseini, M; Mokhtari-Zaer, A; Moradi-Marjaneh, R; Salmani, H, 2020) |
| "Renal hypertension was induced in Wistar strain male albino rats weighing 200-250 g by following the method of Goldblatt." | 1.32 | Differential anxiolytic effect of enalapril and losartan in normotensive and renal hypertensive rats. ( Ramanathan, M; Srinivasan, J; Suresh, B, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Salmani, H | 1 |
| Hosseini, M | 1 |
| Baghcheghi, Y | 1 |
| Moradi-Marjaneh, R | 1 |
| Mokhtari-Zaer, A | 1 |
| Genaro, K | 1 |
| Fabris, D | 1 |
| Fachim, HA | 1 |
| Prado, WA | 1 |
| Reinecke, A | 1 |
| Browning, M | 1 |
| Klein Breteler, J | 1 |
| Kappelmann, N | 1 |
| Ressler, KJ | 1 |
| Harmer, CJ | 1 |
| Craske, MG | 1 |
| Tashev, R | 1 |
| Ivanova, M | 1 |
| Llano López, LH | 1 |
| Caif, F | 1 |
| García, S | 1 |
| Fraile, M | 1 |
| Landa, AI | 1 |
| Baiardi, G | 1 |
| Lafuente, JV | 1 |
| Braszko, JJ | 1 |
| Bregonzio, C | 1 |
| Gargiulo, PA | 1 |
| Srinivasan, J | 1 |
| Suresh, B | 1 |
| Ramanathan, M | 1 |
| Bonini, JS | 1 |
| Bevilaqua, LR | 1 |
| Zinn, CG | 1 |
| Kerr, DS | 1 |
| Medina, JH | 1 |
| Izquierdo, I | 1 |
| Cammarota, M | 1 |
| Shepherd, J | 1 |
| Bill, DJ | 1 |
| Dourish, CT | 1 |
| Grewal, SS | 1 |
| McLenachan, A | 1 |
| Stanhope, KJ | 1 |
| Kaiser, FC | 1 |
| Palmer, GC | 1 |
| Wallace, AV | 1 |
| Carr, RD | 1 |
| Fraser-Rae, L | 1 |
| Hallam, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Losartan on Emotional Processing in Healthy Volunteers[NCT03434054] | 30 participants (Actual) | Interventional | 2016-06-01 | Completed | |||
| Enhancing Fear Extinction Via Angiotensin Type 1 Receptor Inhibition: A Randomized Controlled Trial in Posttraumatic Stress Disorder[NCT02709018] | 149 participants (Actual) | Interventional | 2016-07-16 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) as used here has 20 items, each scored 0-4, to yield a score with a possible range of 0-80. Higher scores mean worse outcome. (NCT02709018)
Timeframe: 10 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| CC Homozygotes on Losartan | 16.7 |
| T Carriers on Losartan | 15.8 |
"Clinician-Administered PTSD Scale for DSM-5 also known as CAPS-5 is the gold standard in PTSD assessment. The CAPS-5 is a 30-item structured interview that can be used to, make current (past month) diagnosis of PTSD, make a lifetime diagnosis of PTSD and assess PTSD symptoms over the past week.~The CAPS-5 as used here has 20 items, each scored 0-4, to yield a score with a possible range of 0-80. Higher scores mean worse outcome." (NCT02709018)
Timeframe: 10 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Losartan | -15.96 |
| Placebo | -16.89 |
1 trial available for losartan and Anxiety
| Article | Year |
|---|---|
Angiotensin Regulation of Amygdala Response to Threat in High-Trait-Anxiety Individuals.
Topics: Adult; Amygdala; Angiotensins; Anxiety; Anxiety Disorders; Brain Mapping; Emotions; Facial Expressio | 2018 |
8 other studies available for losartan and Anxiety
| Article | Year |
|---|---|
Losartan modulates brain inflammation and improves mood disorders and memory impairment induced by innate immune activation: The role of PPAR-γ activation.
Topics: Amyloid beta-Peptides; Angiotensin Receptor Antagonists; Anilides; Animals; Anxiety; Behavior Rating | 2020 |
Angiotensin AT1 receptors modulate the anxiogenic effects of angiotensin (5-8) injected into the rat ventrolateral periaqueductal gray.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Anxiety; Imidazoles; Losartan; Mal | 2017 |
Involvement of hippocampal angiotensin 1 receptors in anxiety-like behaviour of olfactory bulbectomized rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Anxiety; CA1 Region, Hippocampal; | 2018 |
Anxiolytic-like effect of losartan injected into amygdala of the acutely stressed rats.
Topics: Amygdala; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Anxiety Agents; Anxiety; Behavior, | 2012 |
Differential anxiolytic effect of enalapril and losartan in normotensive and renal hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Anx | 2003 |
Angiotensin II disrupts inhibitory avoidance memory retrieval.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; An | 2006 |
Effects of the selective angiotensin II receptor antagonists losartan and PD123177 in animal models of anxiety and memory.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Anti-Anxiety Agents; Anxiety; Biphenyl Co | 1996 |
Antianxiety properties of the angiotensin II antagonist, DUP 753, in the rat using the elevated plus-maze.
Topics: Angiotensin II; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Biphenyl Compounds; Blood P | 1992 |